CMS RBCS · Imaging · Nuclear

PET- Oncology codes

13 CPT®/HCPCS codes, ranked by est. all-Medicare services — scaled from national Medicare Part B fee-for-service volume. Open any code for the full market view — ranked physician groups, geography, and 12-year trend.

CY2024 · National scale is an all-Medicare estimate · est. — scaled estimate — assumes MA utilization mirrors FFS; not an observation; the observed fee-for-service figure is shown adjacent. Part B · national figures

HCPCS · Nuclear imaging A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries CMS descriptor · HCPCS
Medicare Part B claims

First observed 2013 — start of our 12-year window; the code predates it

National scale 527,077 services · est. ▲ 7.9% YoY · 227,400 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 263,767 observed fee-for-service services

See the national market for A9552 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9595 Piflufolastat f-18, diagnostic, 1 millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 474,907 services · est. ▲ 31.8% YoY · 26,803 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 242,774 observed fee-for-service services

See the national market for A9595 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9596 Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 98,487 services · est. ▲ 55.7% YoY · 8,960 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 49,756 observed fee-for-service services

See the national market for A9596 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9800 Gallium ga-68 gozetotide, diagnostic, (locametz), 1 millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2022 — first year this code appears in Part B claims

National scale 13,784 services · est. ▲ 88.7% YoY · 1,224 FFS beneficiary-episodes (CY2024, all-Medicare estimate) — 6,875 observed fee-for-service services

See the national market for A9800 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9588 Fluciclovine f-18, diagnostic, 1 millicurie CMS descriptor · HCPCS
Medicare Part B claims

First observed 2017 — first year this code appears in Part B claims

National scale 292 services · est. · 24 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 151 observed fee-for-service services

See the national market for A9588 → ranked groups · states · 12-yr trend

HCPCS · Nuclear imaging A9597 Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified CMS descriptor · HCPCS
Medicare Part B claims

First observed 2021 — first year this code appears in Part B claims

National scale 68 services · est. ▼ 98.5% YoY · 35 FFS beneficiary-episodes (CY2023, all-Medicare estimate) — 35 observed fee-for-service services

See the national market for A9597 → ranked groups · states · 12-yr trend

7 more CPT-coded procedures — shown with a trial or subscription, under AMA licensing.